At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Peginterferon Lambda-1Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
In Brief
A Phase 2 clinical trial evaluating Peginterferon Lambda-1A for Hepatitis D, Chronic. Completed, enrolled 33 participants across 4 sites in 3 countries.
Detailed Summary
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis D, Chronic
CountriesIsrael, New Zealand, Pakistan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartOct 2016
Primary CompletionJul 2018
Study CompletionDec 2018
TodayJul 2026
First PostedMay 9, 2016
Enrollment StartOct 19, 2016
Primary CompletionJul 20, 2018
Study CompletionDec 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.1 years ago
Interventions
Peginterferon Lambda-1Adrug